Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601465 | 0.86 | CNR2 (0.38) | — | |
| SCHEMBL18415010 | 0.85 | BRS3 (0.38) | ALDH1A1BRS3PDE10ATRPV4 | |
| SCHEMBL19464697 | 0.82 | ALDH1A1 (0.33) | ALDH1A1BRS3PDE10A | |
| SCHEMBL25564702 | 0.81 | NFE2L2 (0.40) | — | |
| SCHEMBL21789410 | 0.79 | CCR1 (0.40) | ALDH1A1 | |
| SCHEMBL18852689 | 0.79 | HPGD (0.40) | ALDH1A1TRPV4 | |
| SCHEMBL23050895 | 0.78 | KDM4E (0.39) | PDE10A | |
| SCHEMBL22601590 | 0.78 | RAB9A (0.36) | ALDH1A1 | |
| SCHEMBL23502493 | 0.77 | PSMD14 (0.32) | — | |
| SCHEMBL18505949 | 0.77 | ALDH1A1 (0.37) | ALDH1A1BRS3PDE10ATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242332-B2 | Method for producing benzimidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-02-08 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-13 | — | — | US | disclosed |
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2020-03-05 | — | — | US | disclosed |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2020-03-05 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | ALDH1A1 1577/4885BRS3 315/4885PDE10A 1004/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | ALDH1A1 1577/4885BRS3 315/4885PDE10A 1004/4885 |
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | ALDH1A1 4349/4885BRS3 1124/4885PDE10A 2766/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | ALDH1A1 263/4885BRS3 3757/4885PDE10A 3281/4885 |
| US-11242332-B2 | Method for producing benzimidazole derivative | CYP3A4, CYP3A5, CYP3A43 | ALDH1A1 268/4885BRS3 1324/4885PDE10A 3227/4885 |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | CYP3A4, CYP3A5, CYP3A43 | ALDH1A1 268/4885BRS3 1324/4885PDE10A 3227/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ALDH1A1 2352/4885BRS3 3189/4885PDE10A 2218/4885 |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | ALDH1A1 2083/4885BRS3 203/4885PDE10A 2027/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | ALDH1A1 263/4885BRS3 3757/4885PDE10A 3281/4885 |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | ALDH1A1 4349/4885BRS3 1124/4885PDE10A 2766/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | ALDH1A1 2352/4885BRS3 3189/4885PDE10A 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.